$ISR investors need a does of reality. $ISR's therapy has been around for almost a decade. ISR is desperately trying to find new areas for this treatment because revenues for the prostate treatment have been falling. If it is no longer a competitive treatment for prostate cancer, then why will it suddenly (after 10 years of use) be the cure-all for other cancers?
Hi Blackbandit! THANKS!! I'm just trying to contribute to this GREAT BOARD, and stop these silly shorts from spreading bad info and fear to new investors.
This morning PR IS AWESOME! THE GAP AT $3.14 is filled!!:)